6-甲基咪唑并[2,1-b][1,3]噻唑-5-甲酸 | 77628-51-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并噻唑类
• 中文名称: 6-甲基咪唑并[2,1-b][1,3]噻唑-5-甲酸
• 中文别名: 6-甲基咪唑[2,1-B][1,3]噻唑-5-甲酸
• 英文名称: 6-methylimidazo[2,1-b][1,3]thiazole-5-carboxylic acid
• 英文别名: 6-methylimidazo[2,1-b]thiazole-5-carboxylic acid
• CAS: 77628-51-4
• 化学式: C₇H₆N₂O₂S
• 分子量: 182.203
• InChiKey: VSQMBZXCDDTZAF-UHFFFAOYSA-N

物化性质

• 熔点：
  164 °C
• 密度：
  1.62±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  82.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934100090
• WGK Germany：
  3
• 储存条件：
  存储条件：2-8°C，密封保存，置于干燥处。

SDS

Name:	6-Methylimidazo[2 1-b][1 3]thiazole-5-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	77628-51-4

Section 1 - Chemical Product MSDS Name:6-Methylimidazo[2 1-b][1 3]thiazole-5-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
77628-51-4	6-Methylimidazo[2,1-b][1,3]thiazole-5-	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 77628-51-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 203 - 205 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H6N2O2S
Molecular Weight: 182.2

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 77628-51-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-Methylimidazo[2,1-b][1,3]thiazole-5-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 77628-51-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 77628-51-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 77628-51-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-甲基咪唑并[2,1-b][1,3]噻唑-5-甲酸 在 草酰氯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.83h， 生成 6-Methylimidazo[2,1-b][1,3]thiazole-5-carbonyl chloride
  参考文献：
  名称：

  新型功能化咪唑并[2,1- b ]噻唑和噻唑并[3,2- a ]嘧啶的合成

  摘要：

  5-Oxo-5 H- [1,3]噻唑并[3,2 - a ]嘧啶-6-羧酸（4）和6-甲基咪唑并[2,1 - b ]噻唑-5-羧酸（17）通过与草酰氯和作为催化剂的N，N-二甲基甲酰胺的反应，使胺与胺6a-i反应成伯和仲酰胺衍生物7-14和19-22。由化合物24制备N，N′-二取代的脲26、27和咪唑并[2，1- b ]噻唑的全氢咪唑并[ 1，5- c ]噻唑29衍生物。通过化合物的核磁共振分析 由图29可知，存在由C7'a的手性中心引起的旋光性和C5N6 '键的旋转受限引起的构象异构性这两种立体异构体的存在。

  DOI：

  10.1002/jhet.5570370115
• 作为产物：
  描述：

  6-甲基咪唑[2,1-B]噻唑-5-羧酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 7.0h， 生成 6-甲基咪唑并[2,1-b][1,3]噻唑-5-甲酸
  参考文献：
  名称：

  发现新的化学实体作为潜在的抗结核分枝杆菌的方法。

  摘要：

  一系列双杂环（1H-吲哚，苯并呋喃，吡唑并[1,5-a]嘧啶，吡唑并[1,5-a]嘧啶-5（4H）-one，咪唑并[2,1-b]噻唑和吡唑并[合成了5，1-b]噻唑）衍生物并评估了它们的抗结核活性。咪唑并[2，1-b]噻唑9a-c和吡唑并[5，1-b]噻唑10a-c在不同程度上表现出有希望的抗结核活性。特别地，2,6-二甲基吡唑并[5,1-b]噻唑10a具有对H37Ra菌株的强抑制作用，MIC值为0.03μg/ mL。化合物10a还显示出良好的药代动力学特征，口服生物利用度（F）为41.7％，半衰期为13.4h。此外，10a显着降低了自发光H37Ra感染的小鼠模型中的细菌负担，表明其开发抗结核药物的潜力很大。

  DOI：

  10.1016/j.bmcl.2016.11.003
• 作为试剂：
  描述：

  叠氮磷酸二苯酯 、 甘氨酸乙酯盐酸盐 在 6-甲基咪唑并[2,1-b][1,3]噻唑-5-甲酸 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以31%的产率得到ethyl N-diphenyl phosphoryl glycinate
  参考文献：
  名称：

  新型功能化咪唑并[2,1- b ]噻唑和噻唑并[3,2- a ]嘧啶的合成

  摘要：

  5-Oxo-5 H- [1,3]噻唑并[3,2 - a ]嘧啶-6-羧酸（4）和6-甲基咪唑并[2,1 - b ]噻唑-5-羧酸（17）通过与草酰氯和作为催化剂的N，N-二甲基甲酰胺的反应，使胺与胺6a-i反应成伯和仲酰胺衍生物7-14和19-22。由化合物24制备N，N′-二取代的脲26、27和咪唑并[2，1- b ]噻唑的全氢咪唑并[ 1，5- c ]噻唑29衍生物。通过化合物的核磁共振分析 由图29可知，存在由C7'a的手性中心引起的旋光性和C5N6 '键的旋转受限引起的构象异构性这两种立体异构体的存在。

  DOI：

  10.1002/jhet.5570370115

文献信息

• [EN] DISUBSTITUTED OCTAHY-DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS<br/>[FR] OCTAHYDROPYRROLO [3,4-C] PYRROLES DISUBSTITUÉS UTILISÉS COMME MODULATEURS DU RÉCEPTEUR DE L'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012145581A1

  公开（公告）日：2012-10-26

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  描述了二取代的八氢吡咯[3,4-c]吡咯化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和病况的方法中有用，比如失眠。
• Highly Selective Dopamine D₃ Receptor (D₃R) Antagonists and Partial Agonists Based on Eticlopride and the D₃R Crystal Structure: New Leads for Opioid Dependence Treatment
  作者：Vivek Kumar、Alessandro Bonifazi、Michael P. Ellenberger、Thomas M. Keck、Elie Pommier、Rana Rais、Barbara S. Slusher、Eliot Gardner、Zhi-Bing You、Zheng-Xiong Xi、Amy Hauck Newman

  DOI：10.1021/acs.jmedchem.6b00860

  日期：2016.8.25

  The recent and precipitous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 receptor (D3R) as a target for therapeutic intervention. Metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clinical use for cocaine abuse. Herein, we report a series of novel and D3R crystal structure-guided

  阿片类镇痛剂滥用和药物过量的近期急剧增加激发了对多巴胺D 3受体（D 3 R）作为治疗干预目标的研究。代谢的不稳定性或预期的毒性阻止了先前报道的D 3 R选择性拮抗剂成功转化为可卡因滥用的临床应用。在本文中，我们报道了一系列新颖且由D 3 R晶体结构引导的4-苯基哌嗪，它们具有异常高的D 3 R亲和力和/或选择性，且具有不同的功效。铅化合物19 d：基于其在体外资料被选择的3 - [R ķ我= 6.84纳米，1700倍d 3R对D 2 R的结合选择性及其在小鼠微粒体内的代谢稳定性。化合物19抑制了羟考酮诱导的小鼠过度运动，并降低了羟考酮诱导的运动敏化。此外，用19进行预处理还可以剂量依赖性地抑制大鼠中羟考酮诱导的条件性位置偏爱（CPP）的获得。这些发现支持D 3 R作为阿片类药物依赖性治疗的靶标，并支持化合物19作为开发的新的先导分子。
• THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Aissaoui Hamed

  公开号：US20100113531A1

  公开（公告）日：2010-05-06

  The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R 1 are as described in the description and their use as medicaments, especially as orexin receptor antagonists.

  本发明涉及式(I)的新噻唑啉衍生物，其中A和R1如描述中所述，以及它们作为药物的使用，尤其是作为食欲素受体拮抗剂的使用。
• Hepatitis C virus inhibitors
  申请人：Hewawasam Piyasena

  公开号：US20070010455A1

  公开（公告）日：2007-01-11

  The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及三肽化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
• [EN] 4-ARYL-BUTANE-1,3-DIAMIDES<br/>[FR] 4-ARYL-BUTANE-1,3-DIAMIDES
  申请人：NOVARTIS AG

  公开号：WO2011073316A1

  公开（公告）日：2011-06-23

  The invention relates to compound of the formula (I): in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  这项发明涉及以下式(I)的化合物：其中取代基如规范中所定义；以自由形式或盐形式存在；其制备方法，其作为药物的用途以及包含它的药物。